TEVAN.UL] failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average.

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a ...

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares.

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...

Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...